COVINGTON, Ky. — CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization was honored at last night’s 2019 Clinical and Research Excellence (CARE) in Boston, Ma.
CTI was named a finalist for the “Medidata Clinical Partnership of the Year Award” in conjunction with Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company with a focus on rare brain and solid tumors, in recognition of their partnership in the clinical development of BXQ-350 for the treatment of cancer.
“It is a privilege to work together with CTI. We are team of people all driven to achieve the same goal, and it clearly has a positive impact on the progression of our program,” comments Ray Takigiku, Ph.D., president and CEO of Bexion. “We are making great strides together in the fight against cancer, and we look forward to seeing what the future will bring for our partnership and program.”
CTI was also named a finalist in the “Most Successful Early Phase Research (Preclinical & Phase I)” category, recognizing the CTI Clinical Research Center team’s work on a recent device study. This category recognizes early phase research projects that met or surpassed its objectives on a range of key performance indicators.
“We are proud of our team and all of the hard work they put in to making our sponsors’ programs a success,” remarks Dr. David Mayleben, VP of Research Site Services at CTI. “We are grateful to the CARE awards committee for recognizing that hard work.”
The 2019 CARE Awards features 11 categories, which showcase significant accomplishments and highlight innovation across the industry – from rare disease drug development and patient centricity in trials and research, to product and technological development, clinical results and collaborative efforts between individuals, departments, or companies. Entries are judged independently by a panel of experts from all core sectors of the clinical R&D industry.